Provectus Biopharmaceuticals, Inc. (PVCT): Operating Income
-$5.29M
Year ended 2025-12-31
-$4.58M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$5.29M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$4.53M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$2.90M | n/m | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | -$3.43M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$4.67M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$4.96M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$6.30M | n/m | 2021-03-02, From 2019-01-01 |
| 2018-12-31 | -$8.05M | n/m | 2020-03-05, From 2018-01-01 |
| 2017-12-31 | -$13.32M | n/c | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | -$24.51M | n/m | 2018-03-23, From 2016-01-01 |
| 2015-12-31 | -$24.65M | n/m | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | -$12.63M | n/m | 2017-03-31, From 2014-01-01 |
| 2013-12-31 | -$13.03M | n/m | 2016-03-30, From 2013-01-01 |
| 2012-12-31 | -$14.34M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$21.44M | n/m | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | -$20.69M | n/m | 2013-03-14, From 2010-01-01 |
| 2009-12-31 | -$12.33M | n/a | 2012-03-14, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | -$12.61M | n/m |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | -$10.45M | n/m |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | -$7.15M | n/m |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | -$9.95M | n/m |
| Medicinova Inc (MNOV) | 2025-12-31 | -$13.28M | n/m |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | -$42.59M | n/m |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | -$338.5K | n/m |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | -$40.11M | n/m |
Compare PVCT, ALLR, HIND, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗